Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs
Tian Zhang(Duke Medical Center), Michael B. Atkins(Georgetown University), Damla Günenç(The University of Texas Southwestern Medical Center), Elad Sharon(National Cancer Institute), Gina Fusaro(Bristol-Myers Squibb (United States)), Mark Stewart(Friends of Cancer Research), Dena Battle, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robyn Burns(Breast Cancer Research Foundation), Patrick M. Forde(Sidney Kimmel Comprehensive Cancer Center), Elizabeth K.S. Barksdale(LUNGevity Foundation), Wendy Selig, Marc Hurlbert(Melanoma Research Alliance), Ryan J. Sullivan(Dana-Farber Cancer Institute)
Cited by 21
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k